Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CD80 (B7-1) is a cell surface glycoprotein belonging to the immunoglobulin superfamily and the B7 family. It is predominantly expressed on antigen-presenting cells (dendritic cells, macrophages, and B cells), as well as activated T cells. CD80 provides the essential "second signal" for full T cell activation via interaction with CD28, lowering the threshold for T cell activation, enhancing proliferation, and promoting cytokine secretion such as IL-2. CD80 also binds CTLA-4, delivering inhibitory signals that regulate tolerance and immune homeostasis. Furthermore, CD80 can interact with PD-L1 and p75 neurotrophin receptor, which modulates the magnitude and output of immune responses. Dysregulation or therapeutic manipulation of CD80 has significant implications in cancer, autoimmune disease, infection, and transplant biology
Blocking CD80/CD86 (prevents co-stimulatory signal to T cells, induces anergy, treats autoimmune diseases); Providing agonist co-stimulation (amplifies effector T cell activation for cancer therapy); Inhibiting CD80/PD-L1 interaction (relieves checkpoint inhibition, restores anti-tumor immunity)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cluster of differentiation 80 (CD80).